Clinical Trial

Randomized Evaluation for Failed TAVR

Study acronym: REVIVE-TAVR
Not Yet Recruiting
View on ClinicalTrials.gov →
Summary
REVIVE TAVR is an acronym for the Randomized Evaluation of Valve-In-Valve versus Explantation for failed TAVR. This is a prospective, multicenter, global randomized trial investigating the safety and efficacy of reintervention for transcatheter heart valve (THV) failure by comparing redo-TAVR (TAV-in-TAV) with TAVR surgical explantation (TAVR-explant) in subjects who are suitable for both options in a real-world clinical setting
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-05-01.
Trial Details
NCT Number NCT06400342
Lead Sponsor Medstar Health Research Institute
Conditions Symptomatic Patients Who Have Had Transcatheter Heart Valve (THV) Failure, Prosthetic Valve Malfunction, Prosthesis Failure
Enrollment 264 participants
Start Date 2025-03-01
Primary Completion 2034-05-01 (estimated)
Study Completion 2036-05-01 (estimated)
Updated on ClinicalTrials.gov 2025-01-24